Caribou Biosciences, Inc.
CRBU
$1.96
$0.0753.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.67M | 2.35M | 2.08M | 2.02M | 3.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.67M | 2.35M | 2.08M | 2.02M | 3.46M |
| Cost of Revenue | 1.30M | 1.74M | 29.86M | 29.82M | 1.99M |
| Gross Profit | 1.37M | 610.00K | -27.79M | -27.80M | 1.47M |
| SG&A Expenses | 10.40M | 9.74M | 10.49M | 5.94M | 11.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.10M | 45.27M | 40.35M | 35.76M | 46.97M |
| Operating Income | -35.43M | -42.91M | -38.28M | -33.74M | -43.50M |
| Income Before Tax | -54.10M | -39.99M | -35.50M | -34.68M | -37.70M |
| Income Tax Expenses | -- | -- | -9.00K | -- | -- |
| Earnings from Continuing Operations | -54.10M | -39.99M | -35.49M | -34.68M | -37.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.10M | -39.99M | -35.49M | -34.68M | -37.70M |
| EBIT | -35.43M | -42.91M | -38.28M | -33.74M | -43.50M |
| EBITDA | -34.26M | -41.75M | -37.09M | -32.56M | -42.65M |
| EPS Basic | -0.58 | -0.43 | -0.39 | -0.38 | -0.42 |
| Normalized Basic EPS | -0.28 | -0.27 | -0.24 | -0.21 | -0.26 |
| EPS Diluted | -0.58 | -0.43 | -0.39 | -0.38 | -0.42 |
| Normalized Diluted EPS | -0.28 | -0.27 | -0.24 | -0.21 | -0.26 |
| Average Basic Shares Outstanding | 93.03M | 92.68M | 91.16M | 90.46M | 90.34M |
| Average Diluted Shares Outstanding | 93.03M | 92.68M | 91.16M | 90.46M | 90.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |